HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.

FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or heart failure enrolled in the ongoing FINEARTS-HF and the completed FIDELIO-DKD and FIGARO-DKD trials.

Interview Questions:

1. What is the importance of this analysis?
2. What trials were included in the analysis?
3. What is the study design of the FINE-HEART study?
4. What are the baseline characteristics of the patients?
5. What are the next steps?

Recorded onsite at HFA 2024, Lisbon.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Jordan Rance, Mirjam Boros
Video Specialist: Dan Brent
Interviewer: Jonathan McKenna